Semaglutide

Social media can be a platform to spread misinformation and reinforce potentially harmful norms in the interest of commercial actors. There are norms related to obesity that commercial actors promote such as "obesity is an individual problem" and the…

OBJECTIVE: Using national claims databases, we sought to emulate the design of the ongoing SEPRA trial and predict its findings, comparing the effects of once weekly semaglutide to SoC medications on glycemic control (A1C <7%) in type-2 diabetes mell…

PURPOSE OF REVIEW: The increasing prevalence of obesity among individuals with type 1 diabetes mellitus (T1DM) presents a significant clinical challenge, as it exacerbates insulin resistance, impairs glycemic control, and increases cardiometabolic ri…

BACKGROUND: Gestational diabetes mellitus (GDM) is a widespread pregnancy complication, affecting approximately 7% to 10% of pregnancies worldwide and presenting risks for both maternal and fetal health. Traditional treatments, including lifestyle ch…

OBJECTIVE: Somapacitan is a long-acting GH approved for once-weekly treatment of GH deficiency (GHD). This study aims to evaluate the efficacy and tolerability of somapacitan after 3 years of treatment and 2 years after switch from daily GH in childr…

Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used as anti-obesity agents, there are individual differences between these agents, thus making it difficult to achieve optimal treatment efficacy. This study aimed to determine…

The 2025 Conference on Retroviruses and Opportunistic Infections (CROI) showcased advances in understanding neuropsychiatric complications among people with HIV (PWH). This review synthesizes key findings related to central nervous system (CNS) reser…

Obesity has been described by the WHO as the largest health threat facing mankind. More than 55% of pregnancies in the United Kingdom occur in women who are overweight or living with obesity. Obesity in pregnancy increases the risk of developing gest…

Semaglutide, a glucagon-like peptide-1 receptor agonist, has emerged as a pivotal therapeutic agent in the management of the cardio-renal-metabolic continuum. Initially developed for glycaemic control in Type 2 diabetes mellitus, its benefits extend…

BACKGROUND: Standard medications for opioid use disorder (MOUD) provide effective treatment pathways for recovery compared with no treatment or behavioral therapies alone. That said, people who continue to use non-prescribed opioids despite treatment…

BACKGROUND: Glucagon-like peptide 1 receptor agonists are a class of drug originally developed to treat type 2 diabetes but now increasingly used for weight loss, especially in people living with obesity. Despite an abundance of evidence about the ef…

The use of the GLP-1R agonist semaglutide is revolutionizing the treatment of obesity, yet its mechanistic effects on energy balance remain elusive. Here, we demonstrate that reactivation of semaglutide-responsive dorsal vagal complex neurons mimics…

BACKGROUND: Pharmacologic therapies for heart failure with preserved ejection fraction (HFpEF) have shown limited efficacy, and the impact of GLP-1 receptor agonists (GLP-1 RAs) remains unclear. This meta-analysis evaluates their effects on mortality…

BACKGROUND: Whether patients with chronic ankle instability (CAI) can benefit from weight loss yielded by using glucagon-like peptide-1 receptor agonists (GLP1-RAs) has remained unclear. METHODS: In this observational study, we recruited more than 20…

BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with significant morbidity and mortality, yet management options remain limited. Although glucagon-like peptide-1 receptor agonists such as…

Cagrilintide (also known as 0833) is an amylin and calcitonin receptor agonist in clinical development for weight management and type-2-diabetes in a fixed-dose combination with semaglutide. Here, we introduce 0174-0839 (0839) as a tool compound for…